Product Description: LLL3 (CLT-005) is a STAT3 inhibitor. LLL3 inhibits dimerization and phosphorylation of STAT3, thereby preventing intraconuclear transfer of STAT3 and inhibits the expression of STAT3 dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of STAT3 persistent activation types of cancer[1][2].
Applications: Cancer-Kinase/protease
Formula: C16H10O4
References: [1]Fuh B, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model[J]. British journal of cancer, 2009, 100(1): 106-112./[2]Lavecchia A, et al. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature[J]. Expert opinion on therapeutic patents, 2014, 24(4): 383-400.
CAS Number: 63972-38-3
Molecular Weight: 266.25
Compound Purity: 97.20
Research Area: Cancer
Solubility: DMSO : 20 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;STAT
Deutsch
English
